UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish
fragment-based drug discovery company, today announced a new research
collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the
world leading provider of molecular interaction analysis tools, and
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of
molecules in order to generate novel therapeutics. The company was spun out
For further information, please contact Dr Per Kallblad, CEO Beactica, +46(0)18-560880.
|SOURCE Beactica AB|
Copyright©2009 PR Newswire.
All rights reserved